Abstract
To the Editor.— Dr. Tennant very courteously reviewed with me the text of his letter toThe Journal. We would like to offer the following comments with respect to it. Eli Lilly and Company shares Dr. Tennant's concern regarding the utilization of propoxyphene napsylate in the treatment of heroin dependent persons. Lilly is cooperating with Dr. Tennant under federal investigational new drug procedures to develop further information on this subject. The administration of propoxyphene napsylate in heroin detoxification and in other drug dependent treatment programs is experimental. There may be side effects associated with the high dosages utilized in such investigational work. Propoxyphene napsylate is not approved by the Food and Drug Administration for use in heroin maintenance and detoxification programs. Lilly does not recommend its utilization for these purposes, as safety and efficacy data are not sufficient to support such use.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
